Prescribing information

 

Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate for the treatment of active AS in adults who have responded inadequately to conventional therapy and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs.

Image of the IL-17A and Cosentyx molecules

Cosentyx is the first and only fully human targeted IL-17A inhibitor approved for use in PsA and axSpA (nr-axSpA and AS)1

IL-17A is a cornerstone cytokine that plays a critical role at inflammation sites associated with PsA and axSpA indications.2,4

 

How does Cosentyx inhibit IL-17A?

Watch this short mechanism of action video to understand the rationale for IL-17A inhibition with Cosentyx.

 

 

Click here for Cosentyx®(secukinumab) prescribing information

Description of the key benefits of Cosentyx around a central molecular image, under the titles: cornerstone cytokine, targeted treatment, downstream action and low immunogenicity

Take the next step

We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.

Or find out more using the links below…

 

Arrow with the text: Hear from the experts. Click image to find out more

Arrow with the text: Why Cosentyx in PsA? Click  image to find out more

Arrow with the text: Why Cosentyx in axSpA? Click image to find out more

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, plaque psoriasis.

  1. Cosentyx Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3669/smpc (Accessed January 2021).
  2. Patel DD et al. Ann Rheum Dis. 20 13;72 (suppl. 2):ii116 -23.
  3. Kirkham B et al. Immunology. 2013;141:133–42.
  4. Miossec P and Kolls JK. Nat Rev Drug Discov. 2012;11:763–76.
  5. Spindeldreher S et al. Dermatol Ther (Heidelb). 2018;8:57–68.
Rate this content: 
No votes yet
UK | February 2021 | 101127
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]